Company Overview

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

  • Name

    Insulet Corporation

  • CEO

    Dr. James R. Hollingshead Ph.D.

  • Website

    www.insulet.com

  • Sector

    Health Care Equipment and Supplies

  • Year Founded

    2000

Profile

  • Market Cap

    $15.14B

  • EV

    $15.75B

  • Shares Out

    70.04M

  • Revenue

    $1,872.7M

  • Employees

    3,000

Margins

  • Gross

    68.39%

  • EBITDA

    19.44%

  • Operating

    15.41%

  • Pre-Tax

    14.28%

  • Net

    21.11%

  • FCF

    10.22%

Returns (5Yr Avg)

  • ROA

    2.56%

  • ROTA

    11.92%

  • ROE

    10.4%

  • ROCE

    6.77%

  • ROIC

    9.54%

Valuation (TTM)

  • P/E

  • P/B

  • EV/Sales

  • EV/EBITDA

  • P/FCF

  • EV/Gross Profit

Valuation (NTM)

  • Price Target

    $236.85

  • P/E

  • PEG

  • EV/Sales

  • EV/EBITDA

  • P/FCF

Financial Health

  • Cash

    $821M

  • Net Debt

    $612.1M

  • Debt/Equity

    1.44

  • EBIT/Interest

    7.44

Growth (CAGR)

  • Rev 3Yr

    23.44%

  • Rev 5Yr

    23.47%

  • Rev 10Yr

    21.33%

  • Dil EPS 3Yr

    126.44%

  • Dil EPS 5Yr

    82.44%

  • Dil EPS 10Yr

    17.6%

  • Rev Fwd 2Yr

    18.37%

  • EBITDA Fwd 2Yr

    25.66%

  • EPS Fwd 2Yr

    17.56%

  • EPS LT Growth Est

    28.2%

Dividends

  • Yield

  • Payout

  • DPS

  • DPS Growth 3Yr

  • DPS Growth 5Yr

  • DPS Growth 10Yr

  • DPS Growth Fwd 2Yr

NasdaqGS:PODD